Frankfurt
22.09.26 | 09:55
0,002 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,003 | 0,003 | 11:26 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Verici Dx unveils new genetic test but shares fall | 2 | Alliance News | ||
| VERICI DX Aktie jetzt für 0€ handeln | |||||
| Mo | Verici Dx kündigt Gentest TranscripTx für Ende 2026 an | 1 | Investing.com Deutsch | ||
| Mo | Verici Dx to launch TranscripTx genetic test in Q4 2026 | 1 | Investing.com | ||
| Mo | Verici Dx PLC - Q4 launch of TranscripTx genetic test | - | RNS | ||
| Fr | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 27.08. | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 11.08. | Verici Dx PLC - Certified Service Provider agreement with Olink | - | RNS | ||
| 04.08. | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 28.07. | Verici Dx PLC - Result of AGM | - | RNS | ||
| 06.07. | Verici Dx PLC - Investor presentation | - | RNS | ||
| 01.07. | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 29.06. | Verici Dx PLC - Final results for the year ended 31 December 2025 | - | RNS | ||
| 25.06. | Verici Dx PLC - Holding(s) in Company | 2 | RNS | ||
| 24.06. | Verici Dx receives New York lab certification for transplant test | 1 | Investing.com | ||
| 24.06. | Verici Dx: Zulassung in New York ermöglicht US-weiten Einsatz von Transplantations-Test | - | Investing.com Deutsch | ||
| 24.06. | Verici Dx PLC - New York State clinical lab certification received | - | RNS | ||
| 23.06. | Verici Dx PLC - Holding(s) in Company | 1 | RNS | ||
| 22.06. | Verici Dx PLC - Result of General Meeting | - | RNS | ||
| 19.06. | Verici Dx PLC - Holding(s) in Company | 1 | RNS | ||
| 12.06. | Verici Dx raises additional £0.19m through retail offer | 2 | Sharecast |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 78,25 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,975 | +0,13 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| NURIX THERAPEUTICS | 25,410 | 0,00 % | Nurix auf Morgan Stanley Healthcare-Konferenz: Roche-Deal als Wachstumstreiber | ||
| ARRIVENT BIOPHARMA | 29,740 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| OBSIDIAN THERAPEUTICS | 17,330 | 0,00 % | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,990 | -0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 299,10 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,260 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,910 | +0,06 % | UBS reiterates Summit Therapeutics stock rating on trial data | ||
| ERASCA | 15,035 | 0,00 % | Propanc Biopharma, Inc.: Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. | ||
| PARABILIS MEDICINES | 36,940 | +0,03 % | Parabilis auf Morgan-Stanley-Konferenz: Umfassende Strategie für Beta-Catenin-Plattform | ||
| ARCUTIS BIOTHERAPEUTICS | 25,975 | +0,06 % | Arcutis auf Morgan Stanley Konferenz: ZORYVE treibt Wachstumsoffensive voran | ||
| TANGO THERAPEUTICS | 22,270 | -0,27 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,115 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RELAY THERAPEUTICS | 18,180 | -0,06 % | Relay Therapeutics auf Morgan Stanley Konferenz: Mehrere Entwicklungschancen mit einem Wirkstoff |
VERICI DX PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,002 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VERICI DX PLC finden Sie auf Wallstreet Online.